The antiarrhythmic drug amiodarone was recently demonstrated to have novel broad range fungicidal activity. We provide evidence that amiodarone toxicity is mediated by disruption of Ca 2؉ homeostasis in Saccharomyces cerevisiae. In mutants lacking calcineurin and various Ca 2؉ transporters, including pumps (Pmr1 and Pmc1), channels (Cch1/Mid1 and Yvc1), and exchangers (Vcx1), amiodarone sensitivity correlates with cytoplasmic calcium overload. Measurements of cytosolic Ca
The emergence of drug-resistant fungi poses an increasing threat to the treatment of opportunistic fungal infections in patients with compromised immune systems, as occurs commonly in cancer and AIDS. This can only be countered by the discovery of new antifungal agents, particularly those that target different molecular pathways, and a better understanding of their mode of action. Recently, the antiarrhythmic drug amiodarone (AMD) 1 was shown to have potent fungicidal activity against not only Saccharomyces but also pathogenic yeasts such as Candida, Cryptococcus, Fusarium, and Aspergillus (1) . Viability of Cryptococcus neoformans after exposure to 10 M AMD fell dramatically, with a 10-fold loss of viable cells after 1 h of treatment and only 0.001% viable cells remaining after 1 day. The cytotoxic effect of AMD appeared to be mediated by calcium, as evidenced by the ability of high (millimolar) concentrations of extracellular Ca 2ϩ to ameliorate drug toxicity (1) and by an increase in cytosolic Ca 2ϩ upon drug application (2) .
There is emerging evidence that cytosolic Ca 2ϩ entry in yeast is critical for survival under a variety of cell stresses, including hyper-and hypo-osmotic shock, protein unfolding agents, and antifungal drugs (3) (4) (5) (6) . The release of calcium from intracellular stores must be compensated by stimulation of extracellular calcium influx, a phenomenon commonly known as capacitative calcium entry (7) . Thus, one possibility is that the cytosolic Ca 2ϩ increase in response to AMD promotes cell survival and is due to capacitative calcium entry, as has been suggested by Courchesne and Ozturk (2) . Paradoxically, excessive or unregulated levels of calcium in the cytoplasm also lead to cell death and are implicated in the cytotoxicity of several drugs (8) as well as fungal toxins (9, 10) . To better understand the role of calcium in AMD toxicity, it is important to distinguish between a capacitative calcium entry mechanism triggered by store depletion or a loss in calcium homeostasis, possibly due to an effect of the drug on ion channels and transporters. The experiments described in this work address these two possibilities and begin to elucidate the cellular basis of AMD toxicity.
We present a detailed investigation of how AMD disrupts Ca 2ϩ homeostasis in Saccharomyces cerevisiae. The roles of different Ca 2ϩ transporters, including pumps (Pmr1 and Pmc1), channels (Cch1, Mid1, and Yvc1), and exchangers (Vcx1), were evaluated in cells lacking these proteins and exposed to relatively low, therapeutically relevant levels of AMD. Pmr1 is an ATP-driven pump that sequesters Ca 2ϩ and Mn 2ϩ into the Golgi/secretory pathway and maintains cellular ion homeostasis under normal growing conditions (11, 12) . Homologues of Pmr1 are widely distributed in organisms including Caenorhabditis elegans, Drosophila, and humans and constitute the newly recognized SPCA subtype of Ca 2ϩ -ATPases (13) . Pmc1 is the yeast Ca 2ϩ pump related to mammalian plasma membrane Ca 2ϩ -ATPases that is induced under calcium stress (14) or in the absence of Pmr1 (12) and serves to detoxify excess Ca 2ϩ by sequestration into the vacuole. Vacuolar calcium sequestration is also accomplished by the H ϩ /Ca 2ϩ exchanger, Vcx1 (15) (16) (17) , which requires the proton electrochemical gradient generated by the vacuolar H ϩ -ATPase. Calcium release from the vacuole is mediated by Yvc1, a transient receptor potential-like Ca 2ϩ channel (18) . Cch1 is the yeast homologue of mammalian voltage-gated calcium channels and, together with the stretch-activated Ca 2ϩ channel Mid1, constitutes a Ca 2ϩ entry channel at the plasma membrane (19) . There is experimental evidence for at least one other calcium influx channel of unknown molecular identity (5, 20) . Together, these proteins regulate cellular calcium levels and are critical for proper functioning of the calcium signaling cascade. Calcium activation of calmodulin and the consequent activation of the calcium-and calmodulin-activated protein phosphatase, calcineurin, are believed to lead to a number of transcriptional and post-translational signals that mediate a variety of different cellular responses to extracellular cues, including cell cycle progression and the protein kinase C-mediated cell wall integrity pathway (reviewed in Refs. 21 and 22) . The conservation of several components of the calcium homeostatic machinery with higher eukaryotes makes yeast an excellent model to study the role of calcium signaling in AMD toxicity.
The results of our analysis of deletion mutants point to a requirement for Pmr1-mediated Ca 2ϩ homeostasis in the growth response to AMD. Similar to recent observations on other drug resistance mechanisms (3, 6) , we also demonstrate a critical role for calcineurin in AMD tolerance. Analyses of cytoplasmic Ca 2ϩ levels by aequorin luminescence assays indicate a correlation between AMD-induced cytosolic Ca 2ϩ increase and growth toxicity. Specifically, AMD seems to cause both Ca 2ϩ influx at the cell membrane and release from internal stores, including the vacuole. To identify additional factors that mediate drug sensitivity, we screened nearly 5000 singlegene deletion mutants for hypersensitivity to AMD. We identify 36 mutants, implicated in known and novel pathways that may be important for drug resistance and detoxification. The results of this study indicate that AMD kills yeast by a mechanism different from that used by conventional antifungals such as the azoles and the polyenes. Finally, we show that low concentrations of AMD and an azole (miconazole and fluconazole) are strikingly synergistic in combination, suggesting that supplementation of conventional antifungal treatment with AMD may be a practical means of converting the fungistatic effect of the azoles into more effective fungicides. In summary, our findings provide important insights into the cellular effects of AMD and its potential efficacy in the treatment of fungal infections.
EXPERIMENTAL PROCEDURES
Yeast Strains and Media-Isogenic sets of yeast deletions were all derived from W303 and have been described before (15) . The MAT␣ S. cerevisiae deletion library was purchased from Research Genetics (Invitrogen). The Q783A and D53A mutations of PMR1 have been described (23, 24) . Candida albicans SC5314 (25) was obtained from the laboratory of Brendan Cormack at The Johns Hopkins University School of Medicine, and C. neoformans (JEC21) (26) was a gift from the laboratory of Joseph Heitman at Duke University Medical Center. All yeast strains were grown in synthetic complete (SC) medium (Bio 101, Inc., Vista, CA) or standard YPD medium (2% Difco yeast extract, 1% bacto-peptone, 2% dextrose) at 30 or 37°C as specified in the legends to Figs. 1, 5, and 6.
Growth Assays for Drug Sensitivity-AMD was purchased from Sigma, dissolved in dimethyl sulfoxide as a 20 mM stock, and stored at Ϫ20°C. 10 l of saturated seed cultures were inoculated in 3 ml of growth medium containing different concentrations of AMD (0 -15 M). Cultures were grown in a 30°C shaker for 24 h, and growth was determined by optical density at 600 nm. To test the effect of divalent cations, AMD sensitivity was monitored in the presence of 10 -25 mM CaCl 2 or 10 mM MgCl 2 . Alternatively, the cation chelator 1,2-bis(2-aminophenoxy)-ethane-N,N,NЈ,NЈ-tetracetic acid (BAPTA; Sigma) was added to final concentrations of 0.5 and 2 mM. To examine the role of calcineurin inhibition, FK506 was diluted from a stock of 0.2 mg/ml to a final concentration of 1 g/ml and added to cell cultures grown in stationary 96-well plates at 30°C.
Miconazole and fluconazole were diluted from a stock of 5 mM (in Me 2 SO) or 2 mg/ml (in water), respectively. In the fluconazole screen with C. albicans, the seed culture was diluted by 1:100 and added to 1 ml of YPD containing different drug concentrations in a 24-well plate. After a 24 -48-h incubation at 37°C, 5 l of cells were diluted into 1.5 ml of YPD containing no drugs and grown overnight. Growth was measured by absorbance at 600 nM. With C. neoformans, 50 l of saturated seed culture was added to 5 ml of YPD supplemented with various drug concentrations. Cells were shaken vigorously for 20 h at 30°C. 5 l of cells exposed to AMD alone or 20 l of cells exposed to both drugs were then diluted in 10 ml YPD and grown to saturation for 24 -48 h. Growth was measured by absorbance at 600 nM.
Genome-wide AMD Sensitivity Screen-200 l of SC medium supplemented with 7 M AMD was added to a 96-well plate and inoculated with 5 l of freshly grown stationary phase yeast culture derived from single-gene deletion strains from the ResGen MAT␣ deletion library (Invitrogen). Control cultures contained an equal volume of dimethyl sulfoxide. The plates were incubated at room temperature for a period of 12-24 h. Cultures were resuspended with a multichannel pipettor, and growth was monitored by measuring the absorbance at 600 nm in a SPECTRAmax 340 microplate reader (Molecular Devices). The relative growth of each strain was expressed as a percentage of A 600 of the control culture (i.e. no AMD). Strains with enhanced sensitivity to AMD were selected based on growth inhibition of 80% or greater relative to control. All candidate strains were retested for enhanced sensitivity in 4 and 8 M AMD.
Aequorin Luminescence Assay-Yeast strains were transformed with plasmid pEVP11-Aeq-89 (4) carrying the aequorin gene and then grown to midlog phase in SC medium lacking leucine. Cells were harvested, incubated with 0.25 mg/ml coelenterazine (Molecular Probes, Inc., Eugene, OR) in the dark for 20 min, washed and resuspended in medium, and then incubated at 30°C for 90 min to allow recovery. AMD (at specified concentrations) was added to 0.3 ml of cells in a cuvette through an injector, and luminescence was immediately recorded every second for 10 min in a luminometer (Lumat LB 9507). The maximal luminescence (L max ) was determined as described (26) . Specifically, cells were lysed with 1% digitonin in the presence of 1 M CaCl 2 , and a peak of RLU was recorded. Calcium concentration was calculated with Equation 1,
where L represents the RLU at a given time point. The base-line calcium concentration of pmc1 in SC and Me 2 SO was ϳ0.38 M, and that of pmr1 was about 0.52 M. Methylene Blue Viability Assay-S. cerevisiae cells grown in media with and without the specified concentrations of AMD and miconazole were stained with methylene blue (Sigma) taken from a stock of 0.1 mg/ml. 250 -300 cells were counted under a light microscope. Dead cells stain blue.
FUN-1 Confocal Microscopy-The Live/Dead yeast viability kit was purchased from Molecular Probes. 50 l of cells grown overnight in the presence or absence of drugs (as specified in Fig. 5 ) were incubated in SC medium at 30°C for 1 h with 4 M FUN-1 dye, which was diluted in SC from a stock of 200 M in Me 2 SO. Immediately after incubation, the cells were examined under a confocal laser-scanning microscope (PerkinElmer UltraView LCI System) equipped with an inverted ϫ 100 oil immersion objective lens. The fluorescent dye was excited at 488 nm by the krypton/argon laser. Conversion of FUN-1 into cylindrical intravacuolar structures was monitored by recording fluorescent micrographs at emission wavelengths of 600 nm (metabolically active and inactive cells) or 520 nm (metabolically inactive cells only). Pseudocolorization was done with Adobe Photoshop software (Adobe Systems Inc.).
RESULTS

Hypersensitivity of the pmr1
Mutant to Amiodarone-To investigate the role of various calcium transport pathways in mediating drug sensitivity, we compared the growth of individual, isogenic gene deletion mutants in media supplemented with micromolar concentrations of AMD. As shown in Fig. 1A , the pmr1 mutant was strikingly more sensitive to AMD; in contrast, the pmc1 null strain showed a small but reproducible tolerance to the drug, relative to wild type. A survey of deletion mutants of the vacuolar H ϩ /Ca 2ϩ exchanger (vcx1) and all known Ca 2ϩ channels in yeast (yvc1, cch1, and mid1) revealed a modest exacerbation of AMD sensitivity in both cch1 and mid1 mutants but not in the others (not shown). Taken together, these results suggest that some aspect of Ca 2ϩ signaling, maintained in large part by the ATP-dependent calcium efflux pump, Pmr1, is important in mediating the growth toxicity of AMD.
Extracellular Calcium Modulates Amiodarone Toxicity-Extracellular calcium has been reported to confer a dose-dependent abrogation of susceptibility to KP4 fungal toxin in the yeast Ustilago maydis (28) . Here, 10 mM CaCl 2 or MgCl 2 appeared to protect cell growth against AMD toxicity, whereas BAPTA, a membrane-impermeant cation chelator, enhanced AMD toxicity, consistent with the removal of Ca 2ϩ (Fig. 1B) . Interestingly, the protective effect of increasing Ca 2ϩ concentrations (10 -25 mM) on AMD sensitivity was most significant in strains lacking Pmr1 (not shown), which may reflect, at least in part, the known dependence of this strain on extracellular Ca 2ϩ for optimum growth (29) . Mn 2ϩ can be a surrogate for Ca 2ϩ in a number of physiological processes but was ineffective in conferring protection (data not shown). Monovalent ions (K ϩ and Na ϩ ) were previously reported to have little or no effect on AMD toxicity to yeast (1) .
Ion Selectivity Mutants of Pmr1 Confirm the Specific Role of Calcium in Amiodarone Toxicity-Since Pmr1 mediates the high affinity transport of both Ca 2ϩ and Mn 2ϩ into the Golgi (11, 24) , it was of interest to determine whether the enhanced sensitivity of pmr1 mutant to AMD was a consequence of a loss of Ca 2ϩ or Mn 2ϩ transport. We have previously described two ion selectivity mutants of Pmr1, Q783A and D53A, which show nearly exclusive transport of either Ca 2ϩ or Mn 2ϩ , respectively (23, 24) . These mutants were expressed in a yeast strain devoid of endogenous Ca 2ϩ pumps, with the additional deletion of calcineurin to maintain viability (pmr1pmc1cnb1) (11, 15) . Selective loss of Ca 2ϩ transport in Pmr1 mutant D53A resulted in loss of tolerance to AMD, similar to the host strain lacking FIG. 1. AMD sensitivity is modulated by calcium. A, Ca 2ϩ pump mutants have differential sensitivities to AMD. Wild-type K601 (WT) and isogenic pmc1 and pmr1 mutants were inoculated into 3 ml of SC media supplemented with AMD as shown and grown for 24 h at 30°C. Growth (optical density at 600 nm) is depicted as percentage of the control culture without drug for each strain. Data points are averages of duplicates, with S.D. values within 5%. One experiment of three is shown. B, divalent cations protect against AMD toxicity. Wild-type K601 (WT) cells were grown in AMD-containing SC medium supplemented with one of the following: CaCl 2 (10 mM), MgCl 2 (10 mM), or BAPTA (0.5 mM or 2 mM) at 30°C for 24 h. Growth was monitored as described above. C, ion selectivity mutants of Pmr1 have differential sensitivities to AMD. Strain K616 (pmr1pmc1cnb1) was transformed with a 2 plasmid carrying wild type Pmr1 or mutants D53A or Q783A and then grown in AMD-supplemented SC medium lacking uracil as described above. Wild type Pmr1 transports both Ca 2ϩ and Mn 2ϩ equally well, whereas mutant D53A is defective in Ca 2ϩ transport, and mutant Q783A is defective in Mn 2ϩ transport. D, loss of calcineurin increases AMD sensitivity. Pairs of isogenic wild type (K601 or BY4742) and mutant strains (pmr1 and cnb1) were grown in SC media containing 4 or 8 M AMD, with FK506 (1 g/ml) added as indicated. Growth was monitored as described above.
Pmr1 and Pmc1 (Fig. 1C) . In contrast, selective loss of Mn 2ϩ transport of mutant Q783A did not alter AMD sensitivity. These results are consistent with the inability of extracellular Mn 2ϩ to protect against AMD toxicity, and they establish the specific role of Ca 2ϩ ions in mediating the cellular effects of the drug.
Loss of Calcineurin Function Enhances Toxicity of Amiodarone-Calcineurin has been shown to be nonessential for normal growth but critical for survival during membrane stress in C. albicans (3) . The enhanced AMD sensitivity of the triple mutant, pmr1pmc1cnb1 (Fig. 1C) relative to the individual gene deletions (Fig. 1A) suggested that loss of calcineurin may be synergistic with loss of the Golgi Ca 2ϩ pump Pmr1. To confirm this, we investigated the effect of FK506 (1 g/ml), a potent inhibitor of calcineurin, on the AMD sensitivity of wild type and pmr1 strains (Fig. 1D) . As predicted, the addition of FK506 exacerbated the AMD sensitivity of the pmr1 mutant. Additionally, the cnb1 mutant, lacking functional calcineurin, displayed increased sensitivity to AMD at higher concentrations of the drug (Fig. 1D) . Taken together, these data confirm the importance of calcineurin in the Ca 2ϩ signaling pathway involved in drug sensitivity.
Amiodarone Triggers Calcium Influx in Yeast Cells-Next,
we investigated whether AMD induced calcium entry into yeast and whether calcium entry correlated with drug sensitivity. Calcium-dependent luminescence of the aequorin-coelenterazine photoprotein complex was monitored in the first few minutes immediately following drug addition. In all strains examined, application of AMD resulted in a biphasic elevation of cytoplasmic calcium that was dependent on AMD concentration (Fig. 2, A-C) . The first peak of calcium occurred extremely fast (within 1-1.5 min) and was followed by a sustained rise that lasted for the duration of the assay. The magnitude of both phases, as well as the kinetics of the initial elevation was steeply dependent on AMD concentration, with maximal increase observed between 10 and 20 M AMD. Elevation of cytosolic calcium was found to correlate with AMD sensitivity; thus, the addition of 10 M AMD elicited the largest luminescence changes in the pmr1 mutant, whereas the pmc1 mutant showed similar changes relative to wild type (Fig. 2D) . Estimated cytosolic calcium concentrations of the initial peak, based on the calibration described under "Experimental Procedures," reached 0.7 M in wild type and pmc1 and close to 1 M in pmr1 cells; the second sustained rise remained around 0.5 stores to the biphasic elevations of cytosolic Ca 2ϩ observed in Fig. 2 . When we used the membrane-impermeant cation chelator BAPTA (5 mM) to deplete extracellular Ca 2ϩ , the first peak of AMD-induced aequorin luminescence in wild type cells was eliminated, indicating that external calcium contributed to the rapid, initial rise in cytoplasmic calcium (Fig. 3A) . Following a short lag, a broad, sustained rise was observed in BAPTAtreated cells that probably corresponded to the second phase of luminescence seen in the absence of BAPTA. These results implied that Ca 2ϩ release from intracellular stores must contribute to cytosolic elevation of Ca 2ϩ and, further, that Ca 2ϩ entry from extracellular sources is not required to trigger release from stores. The transient receptor potential-like channel Yvc1 has been shown to mediate Ca 2ϩ release from the vacuole in response to hypertonic shock (30) . We investigated the contribution of vacuolar Ca 2ϩ release by examining aequorin luminescence in the yvc1 mutant (Fig. 3A) . The changes in intracellular Ca 2ϩ in the yvc1 mutant were essentially similar to wild type in the absence of BAPTA. The first peak of wild type cells reached ϳ0.8 -0.9 M, and that of yvc1 was about 0.7 M. The second sustained rise in both strains ranged from 0.59 to 0.66 M of free calcium. Strikingly, BAPTA treatment completely abolished Ca 2ϩ elevation in the yvc1 mutant. These results indicate that whereas the first peak of AMD-induced cytosolic Ca 2ϩ comes exclusively from outside, the later elevation derives from both extracellular and vacuolar sources.
Courchesne and Ozturk reported that Mid1 could be the channel through which AMD-induced calcium entry occurs. They showed that the Ca 2ϩ transient in mid1 mutant was 5-fold lower than the wild type control although not abolished (2). In Fig. 3B , we show that the addition of the calcium channel blockers La 3ϩ or Al 3ϩ abolished the first elevation of Ca 2ϩ but not the second, reaffirming the conclusion from Fig. 3A that the initial rise in luminescence comes solely from extracellular Ca 2ϩ , whereas the slower increase is derived from both extracellular and intracellular stores. High concentrations (10 mM) of extracellular Ca 2ϩ or Mg 2ϩ also diminished the initial peak, possibly due to desensitization/inactivation of the putative plasma membrane channel (not shown).
Figs. 2 and 3 present the initial elevation of cytosolic Ca 2ϩ being rapidly reversed within the first 1-1.5 min after AMD exposure. In pmr1, the initial rise of calcium is higher, and the decay is slower (Fig. 2D) , suggesting that active Ca 2ϩ transport into the Golgi/secretory pathway by the Pmr1 pump contributes in part to the decay of aequorin luminescence. Since the vacuole is known to be the major store for cellular calcium, we
FIG. 3. Contribution of extracellular and vacuolar stores to AMD-induced Ca
2؉ elevations. A, aequorin luminescence of K601 (WT) and the isogenic yvc1 mutant was monitored upon the addition of 15 M AMD to cells resuspended at a concentration of 1 OD/ml in SC medium with or without BAPTA (5 mM), as indicated. B, the addition of 1 mM Al 3ϩ or La 3ϩ to wild type cells immediately prior to measurement of aequorin luminescence blocked the initial influx of Ca 2ϩ but not the slower rise. All traces were in response to 15 M AMD; the control trace had no ions added. C, the initial peak of luminescence measured in response to 15 M AMD in pmc1vcx1 and pmc1vcx1yvc1 mutants showed a large (14-fold) increase in magnitude relative to an isogenic control strain (yvc1).
hypothesized a significant contribution of vacuolar Ca 2ϩ sequestration in response to AMD-induced calcium influx. Indeed, we saw that in the absence of both known vacuolar Ca 2ϩ transporters, Vcx1 and Pmc1, the first luminescent peak corresponding to extracellular Ca 2ϩ uptake was greatly elevated (Fig. 3C) , with an estimated maximum of 3.3 M (concentration calculation described under "Experimental Procedures"). This is consistent with a prominent role for vacuolar sequestration in the Ca 2ϩ homeostatic mechanism. The disruption of all three known Ca 2ϩ removal pathways, Pmr1, Pmc1, and Vcx1, is known to be nonviable (14) , most likely due to a complete loss of cytosolic Ca 2ϩ homeostasis.
Large Scale Screen of a Yeast Deletion Library for Amiodarone-sensitive Mutants-The S
. cerevisiae gene deletion library offers a powerful tool for the assignment of new functions to sequenced genes. Since AMD is a novel antimycotic with unknown targets in yeast, it was of interest to identify additional genes contributing to AMD sensitivity that might lead to further insight into the cellular mechanism of AMD-mediated toxicity. We twice screened a library of nearly 5000 single, nonessential gene deletions for hypersensitivity to AMD (see "Experimental Procedures"). 15 mutants were identified in the first screen, and 21 more were found in the second screen. They were all retested several times to confirm their drug-sensitive phenotype (Table I ). The identification of pmr1 from this genome-wide screen provided independent verification of the results shown in Fig. 1A . We also found pdr5, a mutant lacking the pleiotropic drug resistance ATPase and widely known to be hypersensitive to a variety of cytotoxic agents (31) . Pdr5 is likely to be involved in detoxification of AMD by mediating drug efflux from the cell. Deletion of individual subunits of the vacuolar H ϩ -ATPase (vma1, vma3, and vma13) abolishes the vacuolar proton electrochemical gradient, which in turn, is likely to limit vacuolar calcium sequestration. The other isolates fell into clusters that include mutants deficient in components of the ergosterol biosynthesis pathway, intracellular trafficking pathways, lipid signaling and kinases, transcription factors, and genes with unknown functions. Some of these strains have been shown previously to have pleiotropic sensitivity to drugs and may be involved with AMD toxicity in a more general rather than specific way. For example, lem3 and cdc50 mutants have deletions in homologous genes of unknown function and are known to be more sensitive to brefeldin A (32) and methyl methanesulfonate and hydroxylurea (33) , respectively. The ergosterol biosynthesis pathway is the primary target of many antifungals (34) , and disruption of this pathway damages the integrity of the cell membrane. It was therefore not surprising to find erg mutants (erg3, erg6, and erg24) with enhanced sensitivity to AMD. However, the discovery of mutants defective in various components of intracellular trafficking pathways, such as cog6, vps16, vps45, vps65, and rcy1 was unexpected. We speculate that mutations in trafficking and signaling pathways might indirectly disrupt Ca 2ϩ homeostasis, resulting in hypersensitivity to AMD.
Based on our results thus far, we have suggested a correlation between AMD sensitivity and increased Ca 2ϩ levels in the cytoplasm. We sought to confirm this hypothesis by examining calcium-dependent luminescence of aequorin in three representative mutants identified from the genome-wide screen for AMD hypersensitivity. As shown in Fig. 4 , all three mutants chosen (vma3, vps45, and rcy1) displayed substantially higher elevations of cytosolic Ca 2ϩ upon the addition of AMD despite the differences in their individual cellular roles. vma3 lacks the H ϩ -transporting subunit c of the vacuolar H ϩ -ATPase (35); vps45 is a vacuolar protein sorting mutant defective in Golgi-or cytosol-to-vacuole transport (36) , and rcy1 is important for endocytosis/recycling at the plasma membrane (37) . In the vma3 and vps45 mutants, upon the addition of AMD the first peak of aequorin luminescence is elevated up to 1.2 M and broadened, suggesting that defects in the function and biogenesis of the vacuole compromise its ability to effectively sequester Ca 2ϩ (Fig. 4A ). The rcy1 mutant had a unique response to AMD, showing significant increases in both luminescence phases such that the first peak, which reached an estimated Ca 2ϩ concentration of 2 M, was not completely abolished before the greatly amplified, second phase occurred (Fig. 4B) . To determine whether the second elevation of calcium in this mutant came from external sources, we examined aequorin luminescence in the presence of BAPTA, added to chelate extracellular calcium. As seen in other strains (Fig. 3) , we showed that the first peak of cytosolic Ca 2ϩ was abolished upon BAPTA treatment, but the second, sustained elevation of Ca 2ϩ remained (Fig. 4B) . Our results suggest AMD-induced release of Ca 2ϩ from internal stores, possibly the vacuole, cannot be effectively cleared from the cytoplasm in the rcy1 mutant. Alternatively, Ca 2ϩ -filled vesicles derived from the Golgi may require the function of the Rcy1 protein for exocytic unloading.
Synergism between AMD and Azoles-Conventional azole antifungals, such as miconazole (MIC) and fluconazole (FLUC), arrest cell growth and are therefore fungistatic rather than fungicidal. A major problem in the long term treatment with azoles is the appearance of resistant fungi. AMD has been reported to have broad range fungicidal effects, particularly against Cryptococcus (1), although the reported minimal inhibitory concentrations may be too high to be practical for treatment without adverse side effects. We first tested the effect of low concentrations of AMD (2-4 M) on cell viability of Saccharomyces in the presence of therapeutic doses of miconazole (1 M). After 24 h of exposure, neither drug alone had significant effect on cell viability, as determined by methylene blue staining (Fig. 5A) . The synergistic effect of the two drugs was seen at all concentrations tested and is shown at 4 M AMD; cell survival fell dramatically from close to 100% in AMD or MIC alone to less than 10% in the presence of both drugs. To examine the metabolic state of drug-treated yeast, cells were stained with the fluorescent dye FUN-1. Without drugs, the cells were metabolically active and able to process FUN-1 into cylindrical intravacuolar structures (Fig. 5B) . On the other hand, when grown in the combined presence of AMD (4 M) and MIC (1 M) for 24 h, nearly all cells turned metabolically quiescent, and FUN-1 remained a green-yellow, diffused stain in the cytoplasm (Fig. 5C) .
Similar findings were observed using the pathogenic yeasts C. albicans and C. neoformans (Fig. 6 ). As reported (1), AMD inhibited growth of both yeasts, whereas an effective dose of FLUC (8 or 16 g/ml) completely prevented cell growth (not shown). Following a 20-h exposure to drugs, cells previously exposed to low levels of AMD (2 or 4 M) or to FLUC (8 or 16 g/ml) alone essentially recovered in drug-free medium, growing to levels approaching control (uninhibited) levels. In contrast, the combination of drugs inhibited regrowth of C. albicans (Fig. 6A) and C. neoformans (Fig. 6B) by 95-98%, indicative of an effective loss of viability. It should be noted that therapeutic plasma levels of 4 M have been reported for AMD and its metabolite, desethylamiodarone (1), suggesting that these clinically relevant doses may be additionally effective in antifungal therapy.
DISCUSSION
AMD is an important therapeutic agent used in the treatment of life-threatening ventricular arrhythmias and supraventricular dysrhythmias (38) . AMD and its active metabolite, desethylamiodarone, are unusual in their long biological half-life (25-110 days) and their broad range of targets. In cardiac cells, AMD inhibits ion channels such as L-type Ca 2ϩ channels and Na ϩ and K ϩ channels, thus prolonging the duration of action potential (39) . Although the therapeutic benefits of AMD are well established, toxic side effects occur in   FIG. 4. AMD-sensitive vma3, vps45 , and rcy1 strains cannot effectively clear Ca 2؉ from the cytosol. Isogenic wild type BY4742 (WT) and mutant strains were treated with 15 M AMD immediately prior to measurement of aequorin luminescence as described under "Experimental Procedures." A, the initial peak of Ca 2ϩ is greatly elevated (and its subsequent decay is slowed) in vma3 and vps45 mutants, relative to WT. B, in the rcy1 mutant, both phases of cytosolic Ca 2ϩ entry are greatly elevated, relative to WT. The addition of BAPTA (5 mM) to the cultures immediately prior to AMD supplement abolished the first peak of Ca 2ϩ in both WT and rcy1 but not the second, slower elevation.
FIG. 5.
Synergism between amiodarone and miconazole in S. cerevisiae. A, wild type S. cerevisiae (BY4742) was grown in SC medium in the absence or presence of AMD (4 M), or MIC (1 M), individually or in combination. After 24 h, the cells were stained with methylene blue and counted as described under "Experimental Procedures." Viability was calculated as the number of unstained cells divided by the total number of cells counted (about 250 -300), expressed as a percentage. The average of three separate experiments is shown. B and C, wild type cells (BY4742) were grown overnight in SC medium without (B) and with both drugs (C) and then stained with 4 M FUN-1 for 1 h at 30°C. Final concentrations of AMD and MIC were 4 M and 1 M, respectively. Excitation wavelength was 488 nm, and emission was at 520 and 600 nm.
FIG. 6.
Synergism between amiodarone and fluconazole in pathogenic fungi. A, C. albicans SC5314 was grown in 1 ml of YPD supplemented with 2 M and 4 M AMD in the presence or absence of 8 g/ml FLUC at 37°C. After 20 h, 5 l of cells were diluted into 1.5 ml of drug-free YPD and grown at 37°C for another 20 h. Growth (absorbance at 600 nm) was plotted as a percentage of control (no drug). Data points are averages of duplicates, with S.D. less than 5%. B, C. neoformans JEC21 was grown in 5 ml of YPD at 30°C, shaken vigorously for 20 h. The medium had 4 M AMD with or without 16 g/ml FLUC. 5 l of cells exposed to AMD alone or 20 l of cells exposed to both drugs were diluted into 10 ml of YPD and grown for 24 -48 h at 30°C until saturation. Growth was measured as optical density at 600 nm and then plotted as a percentage of control (no drug). Data points are averages of duplicates, with S.D. equal to or less than 10%. noncardiac tissues, most prominently the lungs and the thyroid gland. There is evidence that AMD causes apoptosis in thyrocytes (40) and pneumocytes (41) . Alveolar macrophages treated with AMD show defects in endocytosis at the steps after the late endosome and missort lysosomal enzymes to the plasma membrane (42) . Of particular interest to this study are the reports of acute AMD exposure leading to a sustained cytoplasmic Ca 2ϩ rise in synaptosomes (43) and in aortic or pulmonary endothelial cells (44, 45) . Our work demonstrates a correlation between AMD toxicity and increased cytoplasmic Ca 2ϩ levels in S. cerevisiae, exemplifying the conservation of Ca 2ϩ transport and signaling pathways between yeast and higher eukaryotes. Therefore, a better understanding of the cellular basis of AMD toxicity in this simple model organism is relevant to understanding and eventually circumventing the toxic side effects of the drug in humans.
We show that low, micromolar doses of AMD, in the range where growth inhibition is observed, stimulate Ca 2ϩ uptake through a plasma membrane channel that is inhibited by Ca 2ϩ channel blockers such as Al 3ϩ and La 3ϩ and by competition with Mg 2ϩ ions. Courchesne and Ozturk (2) have suggested that one pathway for Ca 2ϩ entry is the stretch-activated channel Mid1. They found that the mid1 mutant was less sensitive to AMD than cch1, suggesting that loss of Cch1 allows Mid1 to function independently. However, we find that the mid1 mutant exhibits enhanced growth sensitivity to AMD similar to that of the cch1 mutant (not shown). The reason for this discrepancy is not clear and warrants further studies.
We provide new evidence for Ca 2ϩ release from the vacuole via the transient receptor potential-like channel, Yvc1. Taken together with a previously published report of the role of this channel in mediating the response to hypertonic shock (30) , it would appear that Yvc1 is the major release mechanism for intracellular stores of Ca 2ϩ in yeast. Whereas depletion of extracellular Ca 2ϩ or the addition of Ca 2ϩ channel blockers abolished the immediate elevation of cytosolic Ca 2ϩ , they did not prevent the Yvc1-mediated release from vacuolar stores, which continued to increase during the time course of the assay. Based on our calculations of calcium concentration, the two phases in WT cells were estimated to correspond to 0.7 and 0.5 M free Ca 2ϩ , respectively, in response to 10 M AMD. In strains hypersensitive to AMD, such as rcy1, these values increased to 2 M and 1.6 -2.5 M, respectively. We speculate that it is the second sustained rise of cytoplasmic Ca 2ϩ that eventually becomes toxic to AMD-treated cells. Given that the sequence of calcium entry from extracellular sources clearly precedes that from intracellular stores in our experiments, we can rule out a role for capacitative calcium entry in the immediate response to AMD, although such mechanisms are likely to contribute to the sustained phase of calcium increase.
It is well known that excessive cytosolic Ca 2ϩ is toxic (46) , and indeed, we show a consistent correlation between hypersensitivity to AMD and excessive elevation of cytosolic Ca 2ϩ . For example, in the absence of the Golgi Ca 2ϩ pump, Pmr1, elevated Ca 2ϩ levels in response to AMD result in a hypersensitive phenotype, consistent with the important role of this pump in the dynamic regulation of cellular Ca 2ϩ levels. Among the deletion strains that we analyzed, only the pmc1 mutant was moderately tolerant to AMD and was seen to have similar elevations of cytosolic Ca 2ϩ , relative to wild type. Paradoxically, very high levels (10 mM) of extracellular Ca 2ϩ or Mg 2ϩ ameliorated the adverse effects of AMD (1) (Fig. 2A) , seemingly in contradiction to our hypothesis. A possible explanation is that the Ca 2ϩ influx pathway(s), probably a Ca 2ϩ channel, is down-regulated in the presence of excess amounts of extracellular Ca 2ϩ . A similar response has been observed in Nicotiana cells exposed to Phytophthora toxins (10), in which calcium influx first increased and then decreased with increasing extracellular Ca 2ϩ levels. In order to gain insight into the molecular target(s) of AMD in yeast, we have defined distinct cellular pathways and components that confer drug sensitivity upon disruption (Table I) . The genome-wide screens were not exhaustive, and it is possible that many other mutants were missed. However, our results are promising, since we have identified several interesting mutants (e.g. erg3, rcy1, vps45) that, with further studies, would shed more light on the molecular basis of AMD toxicity as well as calcium homeostasis in fungi. The enhanced sensitivity of trafficking mutants may be due to defects in drug detoxification and/or Ca 2ϩ clearance via the secretory pathway or vacuolar sequestration. For example, the rcy1 mutant is defective in exit from an early, sorting endosome which has been postulated to receive traffic from the secretory and endocytic pathways (37) . AMD toxicity in the rcy1 mutant might be due to defective traffic of Golgi-or vacuole-derived vesicles loaded with Ca 2ϩ or in the recycling of endocytosed AMD to the plasma membrane. On the other hand, vps45, a Golgi-or cytosol-to-vacuole transport mutant (36) , and vma3, a strain lacking the proton-transporting subunit c of the vacuolar H ϩ -ATPase (35) , are both defective in vacuolar function and biogenesis, so that Ca 2ϩ cannot be effectively sequestered. The drug sensitivity observed in signaling mutants like sac1 and ptc1 is also interesting and unexpected. SAC1 encodes a phosphoinositide phosphatase, in the absence of which the cell contains an irregularly shaped vacuole surrounded by lipid droplets (47) , suggesting that vacuolar function is compromised in this mutant. Ptc1 is a negative regulator of the high osmolarity glycerol pathway and has been shown to maintain the basal kinase activity of Hog1 (48) . Clearly, our findings warrant further investigation to elucidate the relationships between AMD toxicity and PTC1 as well as other genes identified in the screen.
It remains to be determined if AMD directly binds and affects a Ca 2ϩ channel or disrupts an intracellular signaling pathway that then leads to cytosolic Ca 2ϩ entry. We note that in addition to its action on ion channels, other reported cellular activities of AMD and desethylamiodarone encompass binding and activation of heterotrimeric G proteins (49) , inhibition of phospholipases A1 and A2 (50) , and binding and inhibition of calmodulin (51, 52) as well as protein kinase C (53). In any case, our work suggests the possibility of using AMD as a novel, broad range antimycotic that is likely to be effective against even drug-resistant pathogenic fungi. Most, if not all, of the cellular pathways and components identified in our screen for mutants hypersensitive to this drug (Table I ) are expected to be conserved in the pathogenic counterparts of bakers' yeast. Mucosal and systemic fungal infections are among the main killers in immunocompromised patients, and resistant fungi have become increasingly prevalent. Conventional drugs such as the azoles are only fungistatic, whereas others that are fungicidal, such as the polyenes, have harmful side effects that preclude long term treatment (54) . The target of both azoles and polyenes is ergosterol and its biosynthesis pathway. One mechanism of drug resistance is the inactivation of Erg3, a sterol desaturase, which results in the accumulation of 14␣-methylfecosterol, a growth-promoting sterol (55) . In the absence of ergosterol, the erg3 mutant is resistant to both amphotericin B (a polyene) and azoles. Interestingly, the erg3 mutant was identified in our screen for AMD sensitivity (Table I) , suggesting that cytotoxicity of AMD occurs by a mechanism distinct from that of the conventional antifungals. If added to an antifungal regimen, AMD could potentially enhance the efficacy by eliminating cells whose growth is only halted by the other fungistatic drugs. In combination, specificity against pathogenic fungi would be conferred by the azoles, and toxicity would be conferred by AMD. To be useful therapeutically, the low concentrations of AMD that are synergistic with azoles should have minimal toxicity to humans.
Although the strategy of combining different classes of antifungals is theoretically attractive, some drugs, when used concomitantly or sequentially, exert no synergism and may even be antagonistic. Specifically, A. fumigatus, when pretreated with noninhibitory doses of itraconazole (an azole), developed resistance to amphotericin B (a polyene) (56) . A combination of fluconazole (an azole) and caspofungin or anidulafungin (two echinocandins) produced no significant changes in efficacy of individual drugs, although the former targets the ergosterol biosynthesis pathway, whereas the latter two inhibit cell wall synthesis (54) . Therefore, the strong synergism between miconazole or fluconazole and AMD demonstrated in this work promises a potentially effective regimen against severe and lifethreatening fungal infections.
